NCI选择博德研究所及德克萨斯大学作为研究肿瘤分子特性改变的数据生产中心

  近日，美国国家癌症研究所(NCI)确定选择博德研究所（Broad Institute）的基因组学平台及德克萨斯大学MD安德森癌症研究中心来作为未来5年研究计划的数据生产中心，旨在鉴别肿瘤的分子改变特性。
  基因组鉴定中心将会通过3个NCI资助计划来产生数据并且对数据进行分析，其中一项计划就是异常反应研究计划，该计划目的在于开发寻找对于未成功的靶向实验性癌症疗法产生异常个体反应的分子事件。
  第二项计划就是辅助肺癌富集标志物的鉴别及测序试验，该研究计划目的在于为参与临床试验的肺癌患者提供关于生物标志物分类及基因组特性分析的分子数据；而第三项计划则是癌症驱动发现计划，该计划目的是提供额外的统计能力来帮助发现驱动肺癌、结肠癌和卵巢癌的基因突变等。
  作为这项研究计划的一部分，博德研究所将对来自这三项计划中的病人肿瘤样本进行研究分析，来产生全基因组、外显子组及RNA的测序数据；同时MD安德森癌症研究中心将会对病人的样本进行基因组学、转录组学及蛋白质组学的分析，其还将利用反向阶段蛋白质阵列技术来调查患者机体肿瘤的特性。
  MD安德森癌症研究中同时也将支持NCI的癌症治疗和诊断部门、癌症试验部门以及癌症疗法评估程序部。（转化医学网360zhyx.com）
  以上为转化医学网原创翻译整理，转载请注明出处和链接！
转化医学网推荐的新闻阅读：

NCI Taps Broad, MD Anderson to Serve as Genome Characterization Centers

The National Cancer Institute has selected the Broad Institute's Genomics Platform and the University of Texas' MD Anderson Cancer Center to serve as data-production centers for a five-year project that aims to characterize molecular changes found in tumors.

These so-called Genome Characterization Centers will generate and analyze data from three NCI-funded projects. One is the Exceptional Responders Initiative, which aims to explore molecular events involved in extraordinary individual responses to otherwise unsuccessful targeted experimental cancer therapies.

A second project is the Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials, which is aimed at providing molecular data for biomarker classification and genomic characterization of lung cancer patients enrolled in clinical trials. The third is the Cancer Driver Discovery project, which aims to provide additional statistical power to discover driver mutations in lung, colon, and ovarian cancer.

As part of the NCI effort, the Broad will generate whole-genome, exome, and RNA sequencing data from patient tumors for the three projects. For its part, the MD Anderson GCC will perform genomic, transcriptomic, and proteomics analysis of patient samples collected from these studies. The center will use reverse phase protein arrays to investigate tumor tissue.

MD Anderson will also support the efforts of the NCI's Division of Cancer Treatment and Diagnosis, the Cancer Trials Support Unit, and the Cancer Therapy Evaluation Program.

The GCCs are funded by the National Cancer Institute, the National Institutes of Health and the Department of Health and Human Services.